Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03960658 · ClinicalTrials.gov registry record · Phase 1

Ketamine and Prolonged Exposure in PTSD

A Phase 1 study, sponsored by Minneapolis Veterans Affairs Medical Center.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT03960658 is a Phase 1 study that has completed, run by Minneapolis Veterans Affairs Medical Center. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03960658, a Phase 1 study, has completed, sponsored by Minneapolis Veterans Affairs Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

This study aims at investigating the effectiveness of the drug, Ketamine, in combination with Prolonged Exposure (PE) therapy for people suffering from PTSD. Participation in the study includes Ketamine infusions, which occur once a week for three weeks. PE therapy sessions will be scheduled one day after each infusion, and may continue up to 12 weeks. After completely therapy, there will be two monthly follow-up assessment visits.

Interventions

  • DRUG ketamine-enhanced prolonged exposure

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-04-03
Est. Completion 2019-12-04
Phase Phase 1

What the Registry Record Tells You About NCT03960658

The ClinicalTrials.gov registry entry for NCT03960658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Veterans Affairs Medical Center, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ketamine-enhanced prolonged exposure is the first listed.

NCT03960658 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03960658 about?

NCT03960658 is a clinical study titled "Ketamine and Prolonged Exposure in PTSD". This study aims at investigating the effectiveness of the drug, Ketamine, in combination with Prolonged Exposure (PE) therapy for people suffering from PTSD. Participation in the study includes Ketamine infusions, which occur once a week for three weeks. PE therapy sessions will be scheduled one day...

What is the current status of trial NCT03960658?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-04-03. Estimated completion is 2019-12-04.

What interventions are being tested in trial NCT03960658?

The interventions under investigation include: ketamine-enhanced prolonged exposure (DRUG).

Who is sponsoring clinical trial NCT03960658?

This trial is sponsored by Minneapolis Veterans Affairs Medical Center, which has 28 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.